Symbols / ENTA $13.95 +0.43%
ENTA Chart
About
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 404.82M |
| Enterprise Value | 412.15M | Income | -71.54M | Sales | 66.98M |
| Book/sh | 4.36 | Cash/sh | 6.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 120 | IPO | — |
| P/E | — | Forward P/E | -5.63 | PEG | — |
| P/S | 6.04 | P/B | 3.20 | P/C | — |
| EV/EBITDA | -6.05 | EV/Sales | 6.15 | Quick Ratio | 4.34 |
| Current Ratio | 4.44 | Debt/Eq | 152.60 | LT Debt/Eq | — |
| EPS (ttm) | -3.21 | EPS next Y | -2.48 | EPS Growth | — |
| Revenue Growth | 9.80% | Earnings | 2026-05-11 | ROA | -13.47% |
| ROE | -60.01% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -60.45% | Profit Margin | -106.80% | Shs Outstand | 29.02M |
| Shs Float | 20.20M | Short Float | 9.39% | Short Ratio | 10.59 |
| Short Interest | — | 52W High | 17.15 | 52W Low | 4.09 |
| Beta | 0.97 | Avg Volume | 268.19K | Volume | 77.91K |
| Target Price | $20.50 | Recom | Buy | Prev Close | $13.89 |
| Price | $13.95 | Change | 0.43% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$20.50
Mean price target
2. Current target
$13.95
Latest analyst target
3. DCF / Fair value
$-0.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.95
Low
$12.00
High
$28.00
Mean
$20.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-10 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2026-01-09 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-11-14 | init | JP Morgan | — → Overweight | $17 |
| 2025-09-30 | main | WestPark Capital | Buy → Buy | $28 |
| 2025-09-15 | main | Evercore ISI Group | Outperform → Outperform | $12 |
| 2025-09-02 | init | WestPark Capital | — → Buy | $24 |
| 2025-08-12 | main | JMP Securities | Market Outperform → Market Outperform | $25 |
| 2025-06-03 | main | JMP Securities | Market Outperform → Market Outperform | $24 |
| 2025-05-14 | main | JMP Securities | Market Outperform → Market Outperform | $23 |
| 2025-02-11 | reit | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2025-02-11 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-12-24 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-11-26 | main | Baird | Outperform → Outperform | $20 |
| 2024-11-26 | reit | JMP Securities | Market Outperform → Market Outperform | $21 |
| 2024-10-10 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2024-10-09 | reit | JMP Securities | Market Outperform → Market Outperform | $22 |
| 2024-09-27 | reit | JMP Securities | Market Outperform → Market Outperform | $22 |
| 2024-08-06 | main | JP Morgan | Underweight → Underweight | $10 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $27 |
| 2024-05-07 | main | HC Wainwright & Co. | Buy → Buy | $27 |
- Biotech Enanta offers live webcast of Citizens conference talk - Stock Titan ue, 03 Mar 2026 12
- What Makes Enanta Pharmaceuticals (ENTA) a New Buy Stock - Yahoo Finance hu, 12 Feb 2026 08
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st Sat, 20 Dec 2025 08
- Responsive Playbooks and the ENTA Inflection - Stock Traders Daily ue, 03 Mar 2026 09
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting - Business Wire ue, 10 Feb 2026 08
- ENANTA PHARMACEUTICALS Earnings Results: $ENTA Reports Quarterly Earnings - Quiver Quantitative Mon, 17 Nov 2025 08
- Enanta Pharmaceuticals Stock Rises 58% – Here’s An Important Update - Stocktwits Mon, 29 Sep 2025 07
- Enanta Pharma (ENTA): Analyst Reiterates Buy Rating with $20 PT - GuruFocus ue, 10 Feb 2026 08
- Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to Trade - Yahoo Finance Fri, 21 Nov 2025 08
- Understanding the Setup: (ENTA) and Scalable Risk - Stock Traders Daily Fri, 20 Feb 2026 08
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 - Business Wire Mon, 09 Feb 2026 08
- Analysts Are Updating Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Estimates After Its First-Quarter Results - simplywall.st hu, 12 Feb 2026 08
- New Analyst Forecast: $ENTA Given $20 Price Target - Quiver Quantitative Fri, 09 Jan 2026 08
- Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance Mon, 09 Feb 2026 08
- Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock - Business Wire ue, 30 Sep 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | LULY JAY R | Chief Executive Officer | — | 2026-02-12 00:00:00 | D |
| 1 | 6875 | — | — | Stock Award(Grant) at price 0.00 per share. | OR YAT SUN | Officer | — | 2026-02-12 00:00:00 | D |
| 2 | 5493 | — | — | Stock Award(Grant) at price 0.00 per share. | KOWALSKY MATTHEW PAUL | Officer | — | 2026-02-12 00:00:00 | D |
| 3 | 6562 | — | — | Stock Award(Grant) at price 0.00 per share. | KIEFFER TARA LYNN | Officer | — | 2026-02-12 00:00:00 | D |
| 4 | 6562 | — | — | Stock Award(Grant) at price 0.00 per share. | LUU BRENDAN | Officer | — | 2026-02-12 00:00:00 | D |
| 5 | 6875 | — | — | Stock Award(Grant) at price 0.00 per share. | ROTTINGHAUS SCOTT T. | Officer | — | 2026-02-12 00:00:00 | D |
| 6 | 1394 | 19837 | — | Sale at price 14.23 per share. | LUU BRENDAN | Officer | — | 2025-12-05 00:00:00 | D |
| 7 | 798 | 11356 | — | Sale at price 14.23 per share. | ROTTINGHAUS SCOTT T. | Officer | — | 2025-12-05 00:00:00 | D |
| 8 | 323 | 4596 | — | Sale at price 14.23 per share. | CAPPS KATHLEEN S. CPA | Officer | — | 2025-12-05 00:00:00 | D |
| 9 | 4743 | 67493 | — | Sale at price 14.23 per share. | LULY JAY R | Chief Executive Officer | — | 2025-12-05 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 780.00 | 1.09K | 0.00 | 332.00 |
| TaxRateForCalcs | 0.02 | 0.01 | 0.21 | 0.00 |
| NormalizedEBITDA | -71.32M | -104.58M | -123.48M | -119.30M |
| TotalUnusualItems | 39.00K | 73.00K | 83.00K | -27.00K |
| TotalUnusualItemsExcludingGoodwill | 39.00K | 73.00K | 83.00K | -27.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -81.89M | -116.05M | -133.82M | -121.75M |
| ReconciledDepreciation | 4.59M | 2.34M | 2.37M | 2.97M |
| EBITDA | -71.28M | -104.51M | -123.48M | -119.22M |
| EBIT | -75.87M | -106.85M | -125.85M | -122.19M |
| NetInterestIncome | 1.76M | 3.83M | 6.21M | 1.57M |
| InterestExpense | 7.68M | 10.94M | 5.15M | 0.00 |
| InterestIncome | 9.44M | 14.77M | 11.36M | 1.57M |
| NormalizedIncome | -81.93M | -116.12M | -133.82M | -121.84M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -81.89M | -116.05M | -133.82M | -121.75M |
| TotalExpenses | 150.67M | 189.33M | 216.41M | 210.00M |
| TotalOperatingIncomeAsReported | -85.35M | -121.69M | -137.21M | -123.84M |
| DilutedAverageShares | 21.34M | 21.16M | 20.97M | 20.60M |
| BasicAverageShares | 21.34M | 21.16M | 20.97M | 20.60M |
| DilutedEPS | -3.84 | -5.48 | -6.38 | -5.91 |
| BasicEPS | -3.84 | -5.48 | -6.38 | -5.91 |
| DilutedNIAvailtoComStockholders | -81.89M | -116.05M | -133.82M | -121.75M |
| NetIncomeCommonStockholders | -81.89M | -116.05M | -133.82M | -121.75M |
| NetIncome | -81.89M | -116.05M | -133.82M | -121.75M |
| NetIncomeIncludingNoncontrollingInterests | -81.89M | -116.05M | -133.82M | -121.75M |
| NetIncomeContinuousOperations | -81.89M | -116.05M | -133.82M | -121.75M |
| TaxProvision | -1.66M | -1.74M | 2.82M | -433.00K |
| PretaxIncome | -83.55M | -117.79M | -131.00M | -122.19M |
| OtherIncomeExpense | 39.00K | 73.00K | 83.00K | -27.00K |
| OtherNonOperatingIncomeExpenses | 83.00K | -27.00K | ||
| GainOnSaleOfSecurity | 39.00K | 73.00K | 83.00K | -27.00K |
| NetNonOperatingInterestIncomeExpense | 1.76M | 3.83M | 6.21M | 1.57M |
| InterestExpenseNonOperating | 7.68M | 10.94M | 5.15M | 0.00 |
| InterestIncomeNonOperating | 9.44M | 14.77M | 11.36M | 1.57M |
| OperatingIncome | -85.35M | -121.69M | -137.21M | -123.84M |
| OperatingExpense | 150.67M | 189.33M | 216.41M | 210.00M |
| ResearchAndDevelopment | 106.74M | 131.48M | 163.52M | 164.52M |
| SellingGeneralAndAdministration | 43.93M | 57.85M | 52.89M | 45.48M |
| GeneralAndAdministrativeExpense | 43.93M | 57.85M | 52.89M | 45.48M |
| OtherGandA | 43.93M | 57.85M | 52.89M | 45.48M |
| TotalRevenue | 65.32M | 67.64M | 79.20M | 86.16M |
| OperatingRevenue | 65.32M | 67.64M | 79.20M | 86.16M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 21.39M | 21.19M | 21.06M | 20.79M |
| ShareIssued | 21.39M | 21.19M | 21.06M | 20.79M |
| TotalDebt | 57.90M | 55.47M | 26.51M | 25.26M |
| TangibleBookValue | 64.72M | 128.81M | 216.74M | 321.33M |
| InvestedCapital | 64.72M | 128.81M | 216.74M | 321.33M |
| WorkingCapital | 155.78M | 242.32M | 360.00M | 281.89M |
| NetTangibleAssets | 64.72M | 128.81M | 216.74M | 321.33M |
| CapitalLeaseObligations | 57.90M | 55.47M | 26.51M | 25.26M |
| CommonStockEquity | 64.72M | 128.81M | 216.74M | 321.33M |
| TotalCapitalization | 64.72M | 128.81M | 216.74M | 321.33M |
| TotalEquityGrossMinorityInterest | 64.72M | 128.81M | 216.74M | 321.33M |
| StockholdersEquity | 64.72M | 128.81M | 216.74M | 321.33M |
| GainsLossesNotAffectingRetainedEarnings | -339.00K | 302.00K | -1.17M | -3.72M |
| OtherEquityAdjustments | -339.00K | 302.00K | -1.17M | -3.72M |
| RetainedEarnings | -404.93M | -323.04M | -207.00M | -73.18M |
| AdditionalPaidInCapital | 469.77M | 451.34M | 424.69M | 398.03M |
| CapitalStock | 214.00K | 212.00K | 211.00K | 208.00K |
| CommonStock | 214.00K | 212.00K | 211.00K | 208.00K |
| TotalLiabilitiesNetMinorityInterest | 216.01M | 247.84M | 245.54M | 54.08M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 167.46M | 190.30M | 182.75M | 24.25M |
| OtherNonCurrentLiabilities | 111.39M | 135.01M | 160.09M | 454.00K |
| PreferredSecuritiesOutsideStockEquity | 1.31M | 1.35M | 1.42M | 1.42M |
| LongTermDebtAndCapitalLeaseObligation | 54.76M | 53.94M | 21.24M | 22.37M |
| LongTermCapitalLeaseObligation | 54.76M | 53.94M | 21.24M | 22.37M |
| CurrentLiabilities | 48.55M | 57.53M | 62.79M | 29.83M |
| OtherCurrentLiabilities | 30.71M | 34.46M | 35.08M | |
| CurrentDebtAndCapitalLeaseObligation | 3.15M | 1.52M | 5.28M | 2.89M |
| CurrentCapitalLeaseObligation | 3.15M | 1.52M | 5.28M | 2.89M |
| PayablesAndAccruedExpenses | 14.70M | 21.55M | 22.44M | 26.94M |
| CurrentAccruedExpenses | 12.75M | 13.55M | 18.34M | 20.94M |
| Payables | 1.95M | 8.00M | 4.10M | 6.00M |
| AccountsPayable | 1.95M | 8.00M | 4.10M | 6.00M |
| TotalAssets | 280.73M | 376.65M | 462.27M | 375.41M |
| TotalNonCurrentAssets | 76.40M | 76.80M | 39.48M | 63.70M |
| OtherNonCurrentAssets | 3.45M | 3.45M | 4.77M | 4.66M |
| InvestmentsAndAdvances | 0.00 | 29.29M | 108.42M | |
| InvestmentinFinancialAssets | 0.00 | 29.29M | 108.42M | |
| AvailableForSaleSecurities | 29.29M | 108.42M | ||
| NetPPE | 72.94M | 73.35M | 34.71M | 29.75M |
| AccumulatedDepreciation | -23.80M | -25.05M | -23.75M | -21.86M |
| GrossPPE | 96.75M | 98.39M | 58.46M | 51.61M |
| Leases | 38.20M | 13.97M | 13.80M | 7.28M |
| ConstructionInProgress | 0.00 | 22.75M | 1.27M | 2.56M |
| OtherProperties | 37.55M | 40.66M | 22.79M | 23.57M |
| MachineryFurnitureEquipment | 21.00M | 21.01M | 20.59M | 18.20M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 204.34M | 299.85M | 422.79M | 311.71M |
| OtherCurrentAssets | 8.59M | 12.41M | 13.26M | 13.45M |
| RestrictedCash | 0.00 | 608.00K | 0.00 | |
| PrepaidAssets | 13.45M | 14.19M | ||
| Receivables | 6.88M | 38.65M | 39.62M | 49.04M |
| TaxesReceivable | 0.00 | 32.00M | 31.00M | 28.72M |
| AccountsReceivable | 6.88M | 6.65M | 8.61M | 20.32M |
| CashCashEquivalentsAndShortTermInvestments | 188.86M | 248.19M | 369.91M | 249.23M |
| OtherShortTermInvestments | 156.57M | 210.95M | 284.52M | 205.24M |
| CashAndCashEquivalents | 32.30M | 37.23M | 85.39M | 43.99M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -32.17M | -96.71M | -112.21M | -86.91M |
| RepaymentOfDebt | -27.48M | 0.00 | 0.00 | |
| CapitalExpenditure | -12.90M | -17.95M | -9.06M | -2.12M |
| InterestPaidSupplementalData | 8.79M | 11.71M | 1.99M | 0.00 |
| IncomeTaxPaidSupplementalData | 109.00K | 241.00K | 4.90M | 0.00 |
| EndCashPosition | 35.66M | 41.20M | 89.36M | 47.96M |
| BeginningCashPosition | 41.20M | 89.36M | 47.96M | 57.81M |
| ChangesInCash | -5.54M | -48.16M | 41.39M | -9.85M |
| FinancingCashFlow | -26.62M | -27.63M | 198.13M | 20.03M |
| CashFlowFromContinuingFinancingActivities | -26.62M | -27.63M | 198.13M | 20.03M |
| NetOtherFinancingCharges | -26.76M | -27.77M | 195.92M | -1.23M |
| ProceedsFromStockOptionExercised | 145.00K | 147.00K | 2.21M | 21.26M |
| NetIssuancePaymentsOfDebt | -27.48M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | -27.48M | 0.00 | 0.00 | |
| LongTermDebtPayments | -27.48M | 0.00 | 0.00 | |
| InvestingCashFlow | 40.35M | 58.23M | -53.58M | 54.90M |
| CashFlowFromContinuingInvestingActivities | 40.35M | 58.23M | -53.58M | 54.90M |
| NetInvestmentPurchaseAndSale | 53.24M | 76.18M | -44.52M | 57.02M |
| SaleOfInvestment | 262.87M | 383.46M | 328.87M | 228.47M |
| PurchaseOfInvestment | -209.63M | -307.28M | -373.39M | -171.45M |
| NetPPEPurchaseAndSale | -12.90M | -17.95M | -9.06M | -2.12M |
| PurchaseOfPPE | -12.90M | -17.95M | -9.06M | -2.12M |
| OperatingCashFlow | -19.27M | -78.76M | -103.15M | -84.78M |
| CashFlowFromContinuingOperatingActivities | -19.27M | -78.76M | -103.15M | -84.78M |
| ChangeInWorkingCapital | 39.91M | 7.13M | 8.02M | 6.79M |
| ChangeInOtherWorkingCapital | -604.00K | |||
| ChangeInOtherCurrentLiabilities | 1.27M | 4.56M | -2.36M | -3.81M |
| ChangeInOtherCurrentAssets | 4.31M | 6.80M | 4.49M | 4.17M |
| ChangeInPayablesAndAccruedExpense | -1.25M | -6.06M | -3.71M | -6.11M |
| ChangeInAccruedExpense | 58.00K | -5.65M | -2.56M | -1.48M |
| ChangeInPayable | -1.31M | -414.00K | -1.15M | -4.63M |
| ChangeInAccountPayable | -1.31M | -414.00K | -1.15M | -4.63M |
| ChangeInPrepaidAssets | 3.82M | 850.00K | 182.00K | 743.00K |
| ChangeInReceivables | 31.76M | 973.00K | 9.42M | 11.79M |
| ChangesInAccountReceivables | -236.00K | 1.97M | 11.70M | 3.26M |
| OtherNonCashItems | -952.00K | 2.14M | -5.24M | -929.00K |
| StockBasedCompensation | 18.57M | 26.80M | 28.22M | 26.97M |
| AmortizationOfSecurities | 503.00K | -1.14M | -2.86M | 1.17M |
| DeferredTax | 0.00 | 0.00 | 345.00K | |
| DeferredIncomeTax | 0.00 | 0.00 | 345.00K | |
| DepreciationAmortizationDepletion | 4.59M | 2.34M | 2.37M | 2.97M |
| DepreciationAndAmortization | 4.59M | 2.34M | 2.37M | 2.97M |
| Depreciation | 4.59M | |||
| OperatingGainsLosses | 6.00K | 16.00K | 150.00K | 27.00K |
| GainLossOnInvestmentSecurities | 27.00K | |||
| GainLossOnSaleOfPPE | 6.00K | 16.00K | 150.00K | 0.00 |
| NetIncomeFromContinuingOperations | -81.89M | -116.05M | -133.82M | -121.75M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ENTA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|